Revised Classification of Inner Ear Schwannomas
Over the past two decades, there has been increasing interest in the diagnosis and management of schwannomas of the inner ear including hearing rehabilitation with cochlear implants. However, tumor nomenclature and classification within the literature have been variable and oftentimes cumbersome. The term "intralabyrinthine schwannoma" is in common use when describing these tumors but is a potential source of confusion given that people often use the term "labyrinth" or "labyrinthine" to refer to the vestibular component of the inner ear only (i.e., labyrinthectomy or the translabyrinthine approach).During the Ninth Quadrennial Conference on Vestibular Schwannoma and Other Cerebellopontine Angle Lesions in Bergen, Norway, in May 2023, a multidisciplinary group of conference participants met and discussed issues pertaining to current terminology and classifications to enhance clarity and to reflect recent advances in tumor management and hearing rehabilitation.Although a variety of terms have been previously used to describe inner ear schwannomas, consensus was achieved on the term "inner ear schwannoma (IES)" to describe eighth nerve schwannomas of the cochlea, vestibule, or semicircular canals. Subgroups under this term comprise intravestibular, intracochlear, or intravestibulocochlear inner ear schwannomas (low complexity tumors), inner ear schwannomas with transfundal extension into the internal auditory canal but without modiolar involvement (intermediate complexity tumors), and inner ear schwannomas with transfundal extension with modiolar involvement (high complexity tumors).The details of the recommendations for an updated and simplified tumor nomenclature centered around tumor control and hearing rehabilitation with cochlear implantation are presented.
Authors
- Stefan K. Plontke (ORCID: https://orcid.org/0000-0002-5424-7688)
- Ja‐Won Koo (ORCID: https://orcid.org/0000-0002-5538-2785)
- Simon Lloyd (ORCID: https://orcid.org/0000-0003-3433-0879)
- Ashley M. Nassiri (ORCID: https://orcid.org/0000-0001-9665-1868)
- Simon Freeman (ORCID: https://orcid.org/0000-0002-6430-2206)
- Torsten Rahne (ORCID: https://orcid.org/0000-0003-1859-5623)
- Jonas Scheffler (ORCID: https://orcid.org/0009-0003-6663-8920)
- Riccardo Di Micco (ORCID: https://orcid.org/0000-0002-6799-3241)
- Christoph Arnoldner (ORCID: https://orcid.org/0000-0003-0066-810X)
- Christine M. Lohse (ORCID: https://orcid.org/0000-0001-9888-7495)
- Samuel P. Gubbels
- John P. Marinelli (ORCID: https://orcid.org/0000-0003-2350-8942)
- Daniele Borsetto (ORCID: https://orcid.org/0000-0003-3464-2688)
- Nigel Biggs
- S. Kösling
- Per Cayé‐Thomasen (ORCID: https://orcid.org/0000-0002-6837-694X)
- Jeanette Hess-Erga (ORCID: https://orcid.org/0000-0002-7476-2070)
- Matthew L. Carlson
Institutions
- Mayo Clinic (US)
- Manchester Academic Health Science Centre (GB)
- Haukeland University Hospital (NO)
- Manchester Royal Infirmary (GB)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- Seoul National University Bundang Hospital (KR)
- University of Manchester (GB)
- Medizinische Hochschule Hannover (DE)
- St Vincent's Hospital Sydney (AU)
- Salford Royal Hospital (GB)
- Mayo Clinic in Florida (US)
- University Hospital in Halle (DE)
- Addenbrooke's Hospital (GB)
- University of Colorado Anschutz Medical Campus (US)
- Medical University of Vienna (AT)
- University of Colorado Denver (US)
Publication Details
- Journal
- Otology & Neurotology
- Published
- 2024-10-28
- DOI
- https://doi.org/10.1097/mao.0000000000004363
- Citations
- 15
- Primary Topic
- Meningioma and schwannoma management
- Type
- article
- Field-Weighted Citation Impact
- 5.80
Funders
- MED-EL Medical Electronics